A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Lymphoma
Advanced or Metastatic Solid Tumors · Non-Hodgkin Lymphoma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 24 (final count)
- Started
- Apr 21, 2025
- Main results expected
- Apr 23, 2026
- Fully finished
- Apr 23, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Incidence of Dose Limiting Toxicities (DLTs)
Measured over: 4 weeks
Incidence of treatment emergent adverse events
Measured over: 24 months
Incidence of changes in clinical laboratory abnormalities
Measured over: 24 months
Overall response rate (ORR) by response evaluation criteria in solid tumors (RECIST) 1.1 and the immune-overall response rate (iORR) by immune RECIST (iRECIST; Part 2, Arms A and B) or response by Lugano classification (Part 2, Arm C)
Measured over: 24 months
Duration of response (DOR) by response evaluation criteria in solid tumors (RECIST) 1.1 and immune RECIST (iRECIST; Part 2, Arms A and B) or based on Lugano classification (Part 2, Arm C)
Measured over: 24 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06939283 · record last updated 2026-10-19 · checked 2026-11-09 15:42 UTC